Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromsø study 2001

Author： Hartz Ingeborg   Eggen Anne   Grimsgaard Sameline   Skjold Frode   Njølstad Inger  

Publisher： Springer Publishing Company

ISSN： 0031-6970

Source： European Journal of Clinical Pharmacology, Vol.60, Iss.9, 2004-11, pp. : 643-649

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The Role of Niacin in Lipid-lowering Treatment: Are we Aiming Too High?

By  

Current Pharmaceutical Design, Vol. 19, Iss. 17, 2013-05 ,pp. : 3094-3106

Bentham Science Publishers

Access to resources Recommend Favorite

New prospects for lipid-lowering drugs

By Thompson G.R.   Naoumova R.P.  

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 5, 1998-05 ,pp. : 715-727

Informa Healthcare

Access to resources Recommend Favorite

Lipid-Lowering Therapy in Patients with Average Cholesterol and High Cardiovascular Risk, Insights from the Heart Protection Study

By Salam Amar  

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 5, 2004-09 ,pp. : 387-389

Springer Publishing Company

Access to resources Recommend Favorite

National guidelines for lipid-lowering therapy unsatisfactory

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 348, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Cardiovascular co-medication among users of antiobesity drugs: a population-based study

By Amundsen Merethe  

Pharmacy World and Science, Vol. 32, Iss. 6, 2010-12 ,pp. : 752-758

Springer Publishing Company

Access to resources Recommend Favorite